Tirzepatide vs Semaglutide: How the Two GLP-1 Options Compare
If you are weighing tirzepatide against semaglutide, you are asking one of the most common questions in weight management today. Both are prescription injectables, both are used to support weight loss, and both are available in compounded form through telehealth. Here is a plain-language look at how they differ — and why the choice between them is ultimately a clinical decision your provider makes, not one to settle from a comparison chart.
Key takeaways
Semaglutide targets one hormone pathway (GLP-1). Tirzepatide targets two (GLP-1 and GIP). That is the core mechanistic difference between them.
Both are available through Ondra as compounded medications. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA does not review them before marketing.
Which medication is appropriate for you depends on your individual health history — it is a decision a licensed provider makes, not one you self-select.
The short answer
Semaglutide and tirzepatide are both prescription medications used in weight management, and both belong to a broader family of treatments that act on gut hormones involved in appetite and blood sugar. The simplest way to describe the difference: semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GLP-1 and GIP receptor agonist. In other words, tirzepatide acts on two hormone pathways where semaglutide acts on one.
Whether that difference translates into a better fit for you is not something a comparison article can answer. It depends on your health history, your goals, how your body responds, and a provider's clinical judgment. This article explains the differences in plain terms so you can have a more informed conversation — not so you can make the decision alone.
A quick note on what this article is — and isn't
This is general educational information from a telehealth platform, not medical advice. Ondra Health is not your doctor, and nothing here decides which medication is right for you. Only a licensed provider can do that, after reviewing your individual health history.
How each one works
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both naturally occurring hormones involved in appetite regulation and blood-sugar control. Medications in this category are designed to mimic the activity of these hormones.
Semaglutide mimics GLP-1 alone. Tirzepatide engages both GLP-1 and GIP receptors, which is why it is often described as dual-action. That dual mechanism is the headline difference people cite, but "more pathways" does not automatically mean "better for everyone" — the right choice is individual and clinical.
What they have in common
Despite the mechanistic difference, semaglutide and tirzepatide share a great deal. Both are weekly injectable medications. Both are typically started at a low dose and increased gradually over time under provider guidance, an approach known as titration. Both are prescription-only, meaning a licensed provider must evaluate you and determine whether treatment is appropriate. And through Ondra, both are available in compounded form, prepared by licensed pharmacies.
Compounded, not brand-name
The semaglutide and tirzepatide available through Ondra are compounded medications — not brand-name products like Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they are marketed. Whether a compounded option is appropriate for you is a decision your licensed provider makes based on your individual health.
So which one is "better"?
This is the question everyone wants answered, and the honest answer is that there is no universal "better." The two medications differ in mechanism, dosing schedules, and how individuals respond to them. Factors a provider may weigh include your health history, other medications you take, how your body tolerates treatment, and your specific goals.
Some people do well on one and not the other. Some start on one and switch later. None of that can be predicted from an article — it emerges from a clinical evaluation and, often, from how treatment actually goes over time. The most useful thing you can do is complete an online visit so a licensed provider can weigh these factors with your individual health in view.
How to get started with either through Ondra
Ondra is a telehealth platform that connects you with licensed providers. You complete an online visit, a licensed provider reviews your information to determine whether semaglutide, tirzepatide, or neither is appropriate for you, and if treatment is appropriate, your provider builds a plan and it ships to your door. You also get ongoing support for questions and refills.
Ondra does not decide between the two medications for you — your provider does. The platform's role is to make that licensed care accessible, transparent, and convenient.
Frequently asked questions
What is the main difference between tirzepatide and semaglutide?
Semaglutide is a GLP-1 receptor agonist, meaning it acts on one hormone pathway. Tirzepatide is a dual GLP-1 and GIP receptor agonist, meaning it acts on two. That mechanistic difference is the core distinction, though whether it matters for any individual is a clinical question.
Is tirzepatide stronger than semaglutide?
Framing one as simply "stronger" oversimplifies the picture. They work through different mechanisms, and individual responses vary. Which is appropriate for you — and what to expect — is a determination a licensed provider makes based on your health history, not something to conclude from a general comparison.
Can I switch from one to the other?
Some people do change medications over the course of treatment, but that is always a provider-guided decision. If you are already in treatment and considering a change, that conversation belongs with the licensed provider overseeing your care.
Are both available as compounded medications?
Yes. Through Ondra, both semaglutide and tirzepatide are available in compounded form, prepared by licensed pharmacies. Compounded medications are not FDA-approved. Whether a compounded option is appropriate for you is a decision your licensed provider makes.
How do I decide which one to ask about?
You don't have to decide before you start. The online visit exists so a licensed provider can help determine which option, if any, fits your situation. You can share your goals and questions, and the provider brings the clinical judgment.
† This article is for informational purposes only and does not constitute medical advice. Ondra Health is a telehealth platform, not a medical provider, and this content does not establish a provider-patient relationship or replace personalized guidance from a licensed professional. Whether semaglutide, tirzepatide, or any GLP-1 treatment is appropriate for you is a decision made by a licensed provider based on your individual health. The medications offered through Ondra are compounded; compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Individual results vary. Availability and program details are subject to change.